title: [Loss of differentiation of a prostate adenocarcinoma after hormone therapy: the example of a metastasis in the spongy body of the penis].
abstract: Penile metastases are very uncommon. Prostate cancer as the most frequent malignoma of the male is the main primary lesion. Metastases in the penis only occur at an advanced state of the tumour and with a high dedifferentiation, e. g., ductal adenocarcinoma. Changes in the morphology of the prostate carcinoma are specially known for the occurrence of small-cell neuroendocrine and undifferentiated carcinomas. Often prior to the transformation an anti-androgen therapy has been undertaken. At this state of the disease, there is only the possibility of a palliative therapy with a poor prognosis. The increasing histological dedifferentiation of the tumour tissue can make it difficult or even impossible to identify the primary lesion.
authors.affiliation: Klinik für Urologie und Kinderurologie, Ammerland Klinik GmbH, Westerstede. dr.uphoff@gmx.de
authors.forename: J
authors.initials: J
authors.lastname: Uphoff
authors.forename: J
authors.initials: J
authors.lastname: Woziwodzki
authors.forename: S O
authors.initials: SO
authors.lastname: Schattka
authors.forename: A
authors.initials: A
authors.lastname: Kollias
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000473:pathology / Q000556:secondary* / Q000601:surgery; D000368:Aged; D000726:Androgen Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis; D001706:Biopsy; D001859:Bone Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000556:secondary / Q000601:surgery; D002280:Basal Cell Carcinoma / Q000188:drug therapy / Q000473:pathology / Q000556:secondary* / Q000601:surgery; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy / Q000473:pathology / Q000556:secondary* / Q000601:surgery; D002471:Cell Transformation, Neoplastic / Q000187:drug effects / Q000473:pathology*; D003131:Combined Modality Therapy; D015653:Cystectomy; D003937:Diagnosis, Differential; D004164:Diphosphonates / Q000627:therapeutic use*; D018450:Disease Progression; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors*; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D009367:Neoplasm Staging; D009378:Neoplasms, Multiple Primary / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D010412:Penile Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000556:secondary* / Q000601:surgery; D010413:Penis / Q000473:pathology / Q000601:surgery; D011467:Prostate / Q000473:pathology / Q000601:surgery; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D004164:Diphosphonates; D007987:Gonadotropin-Releasing Hormone